Troxipide in the Management of Gastritis: A Randomized Comparative Trial in General Practice

Table 3

Mean Visual Analog Scale (VAS) scores for Gastritis symptoms in patients at baseline, week 2 and week 4.

	Troxipide; Mean VAS Score (±SD)	Ranitidine; Mean VAS Score (±SD)	𝑃-values for difference between treatments
Abdominal Pain
Baseline	61.55±11.66	56.47±10.97
Week 2	34.78±10.67^∗	37.04±10.87^∗	<.01
Week 4	10.98±9.43^∗	22.67±9.70^∗	<.01
Bloating
Baseline	52.98±16.61	48.15±18.94
Week 2	27.01±13.93^∗	31.38±15.49^∗	<.01
Week 4	7.76±10.56^∗	16.92±14.78^∗	<.01
Belching
Baseline	43.41±20.11	42.58±17.83
Week 2	20.23±16.21^∗	23.84±14.43^∗	N.S
Week 4	2.04±6.32^∗	10.51±13.16^∗	<.05
Nausea
Baseline	32.74±18.01	32.42±15.82
Week 2	9.61±11.48^∗	14.6±13.58^∗	N.S
Week 4	0.19±1.40^∗	3.4±8.72^∗	N.S
Vomiting
Baseline	17.85±14.23	20.0±11.54
Week 2	5.0±11.6^∗	3.84±5.06^∗	N.S
Week 4	0.0^∗	0.76±2.77^∗	N.S
Loss of Appetite
Baseline	32.75±19.25	30.91±19.97
Week 2	10.34±10.85^∗	13.63±10.02^∗	N.S
Week 4	0.34±1.85^∗	0.91±2.94^∗	N.S
Heartburn
Baseline	49.31±15.32	42.85±16.58
Week 2	21.37±11.15^∗	26.73±12.81^∗	<.01
Week 4	2.75±6.15^∗	11.63±9.5^∗	<.01

^∗𝑃 Value less than  .01 versus baseline, within the group.
NS: not significant (𝑃>.05).